title: Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
authors: St. Mary's Hospital Campus of Imperial College, St. Mary's Hospital, Praed Street, London, W2 1NY, United Kingdom. b.bain@imperial.ac.uk
authors: Barbara J
authors: BJ
authors: Bain
authors: Catherine
authors: C
authors: Garnett
authors: Simona
authors: S
authors: Deplano
authors: Kikkeri
authors: K
authors: Naresh
authors: Ed
authors: E
authors: Kanfer
mesh_terms: D000368:Aged; D019943:Amino Acid Substitution; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001241:Aspirin / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D019070:Cell Lineage; D002471:Cell Transformation, Neoplastic / Q000473:pathology*; D006098:Granulocytes / Q000473:pathology*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D053614:Janus Kinase 2 / Q000235:genetics / Q000378:metabolism; D008297:Male; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D013920:Thrombocythemia, Essential / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D010975:Platelet Aggregation Inhibitors; C507924:JAK2 protein, human; D053614:Janus Kinase 2; D001241:Aspirin; D006918:Hydroxyurea